The president of the University of Texas MD Anderson Cancer Center, Dr. Ron DePinho, has been nominated along with ten other leaders in the oncology field as a fellow of the American Association for Cancer Research (AACR) Academy. The academy is formally inducting their new fellows, distinguished due to their contributions to cancer research, at its AACR Annual Meeting 2015, to be held between April 18 and 22 in Philadelphia.
In recognition of their efforts to advance cancer research, the new class of AACR fellows was selected by a group of fellows through a peer-review process and ratified by the academy’s Executive Committee. As part of the process, each candidate is evaluated based on scientific achievements involving both cancer research and cancer-related biomedical sciences.
“Our 2015 class of fellows includes 11 luminaries in the cancer research field, in honor of the 11 founders of the AACR in 1907,” said the CEO of AACR, Margaret Foti, MD, PhD. “We’re delighted to recognize the incredible scientific accomplishments of these illustrious researchers and celebrate how their dedicated efforts have helped accelerate the pace of progress against many of the hundreds of diseases we collectively call cancer.”
The academy believes these global leaders are helping advance cancer research by providing insights about the future of oncology treatment and patient care, and may help AACR continue its work towards the prevention and cure for all types of cancer.
“Dr. DePinho’s outstanding work in basic and translational research in cancer, aging and age-associated degenerative disorders has been internationally recognized,” said The University of Texas System Chancellor William H. McRaven. “His selection as a member of this notable academy is further testament to his significant contributions to cancer science.”
In addition to Dr. DePinho, other new fellows of the academy include the director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Kenneth C. Anderson, the director of the Center for Cancer Targeted Therapies, Carlos L. Arteaga, the senior group leader of the Division of Molecular Genetics, Netherlands Cancer Institute, Anton J.M. Berns, the director of clinical research at the Massachusetts General Hospital, Bruce A. Chabner, and the CEO of the Bill and Melinda Gates Foundation, Susan D. Desmond-Hellmann.
In addition, Robert N. Eisenman from the Fred Hutchinson Cancer Research Center, Douglas R. Lowy, the deputy director of the Center for Cancer Research, Carol L. Prives, professor at Columbia University, Steven A. Rosenberg, chief of surgery at the National Cancer Institute, and Craig B. Thompson, president and CEO of the Memorial Sloan Kettering Cancer Center were also distinguished as AACR fellows.
Dr. DePinho now becomes the eighth MD Anderson faculty member to be named an AACR fellow. Emil J. Freireich, the physician who pioneered the use of drug combinations to treat cancer in order to reverse the bleak survival prospects of children with leukemia and James Allison, who is a basic scientist who found a new way to treat cancer with the immune system, were also recently nominated as members of the institution. Isaiah Fidler, Waun Ki Hong, Margaret Kripke, John Mendelsohn, and Louise Strong are the other fellows affiliated to MD Anderson.